产业新闻丨武田公布TYK2抑制剂治疗银屑病3期临床研究积极结果

医药观澜
Dec 20, 2025

武田制药计划在即将举行的医学会议上公布研究数据,并计划自2026财年向美国FDA及其他监管机构递交新药上市申请(NDA)。Zasocitinib是一款在研的新一代高选择性口服TYK2抑制剂,可在24小时内持续抑制IL-23以及其他驱动疾病进展的核心免疫通路。它有潜力成为免疫介导炎症性疾病患者的领先口服治疗选择。根据体外研究数据,zasocitinib对TYK2的选择性比对其他JAK酶高出一百万倍...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10